Improved ex vivo expansion of adult hematopoietic stem cells by overcoming CUL4-mediated degradation of HOXB4.

TitleImproved ex vivo expansion of adult hematopoietic stem cells by overcoming CUL4-mediated degradation of HOXB4.
Publication TypeJournal Article
Year of Publication2013
AuthorsLee J, Shieh J-H, Zhang J, Liu L, Zhang Y, Eom JYong, Morrone G, Moore MAS, Zhou P
JournalBlood
Volume121
Issue20
Pagination4082-9
Date Published2013 May 16
ISSN1528-0020
KeywordsAdult, Adult Stem Cells, Animals, Cell Culture Techniques, Cell Proliferation, Cells, Cultured, Cullin Proteins, Feasibility Studies, HeLa Cells, Hematopoietic Stem Cells, Homeodomain Proteins, Humans, Mice, Mice, Inbred NOD, Mice, SCID, Mice, Transgenic, Primary Cell Culture, Protein Engineering, Proteolysis, Transcription Factors
Abstract

Direct transduction of the homeobox (HOX) protein HOXB4 promotes the proliferation of hematopoietic stem cells (HSCs) without induction of leukemogenesis, but requires frequent administration to overcome its short protein half-life (∼1 hour). We demonstrate here that HOXB4 protein levels are post-translationally regulated by the CUL4 ubiquitin ligase, and define the degradation signal sequence (degron) of HOXB4 required for CUL4-mediated destruction. Additional HOX paralogs share the conserved degron in the homeodomain and are also subject to CUL4-mediated degradation, indicating that CUL4 likely controls the stability of all HOX proteins. Moreover, we engineered a degradation-resistant HOXB4 that conferred a growth advantage over wild-type HOXB4 in myeloid progenitor cells. Direct transduction of recombinant degradation-resistant HOXB4 protein to human adult HSCs significantly enhanced their maintenance in a more primitive state both in vitro and in transplanted NOD/SCID/IL2R-γ(null) mice compared with transduction with wild-type HOXB4 protein. Our studies demonstrate the feasibility of engineering a stable HOXB4 variant to overcome a major technical hurdle in the ex vivo expansion of adult HSCs and early progenitors for human therapeutic use.

DOI10.1182/blood-2012-09-455204
Alternate JournalBlood
PubMed ID23520338
PubMed Central IDPMC3656448
Grant ListCA098210 / CA / NCI NIH HHS / United States
CA118085 / CA / NCI NIH HHS / United States
Related Lab: 
Related Faculty: 
Pengbo Zhou, Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700